British drugmaker GSK has agreed to acquire U.S. cancer-focused biotechnology company Nuvalent for $10.6 billion, strengthening its oncology portfolio with three experimental lung cancer treatments.
The deal, announced on Tuesday, includes two late-stage therapies, zidesamtinib and neladalkib, which GSK said could be launched before the end of 2026, which is subject to regulatory approval.
GSK Chief Executive Luke Miels said the two treatments had the potential to become best-in-class medicines and could reach the market as early as this year if approved by U.S. regulators.
The Pharmaceutical giant said it expects to complete the acquisition later in 2026, enabling it to accelerate the development and commercialisation of Nuvalent’s cancer drug pipeline.”GSK’s proven track record, infrastructure, and expertise will support the successful commercialisation of zidesamtinib and neladalkib, as well as accelerate advancement of our broader discovery pipeline,” Nuvalent Chief Executive James Porter said in a statement.
The acquisition comes as pharmaceutical companies continue to navigate uncertainty resulting from U.S. President Donald Trump’s efforts to encourage domestic investment and reduce prescription drug costs through tariff threats and policy measures.
GSK and several other major non-U.S. drugmakers agreed in December 2025 to lower prices for certain prescription medicines sold in the United States in exchange for tariff exemptions within a three year period.
Miels assumed the role of chief executive in January, succeeding Emma Walmsley after nearly nine years at the helm of the British pharmaceutical group. He previously served as GSK’s chief commercial officer.